The Natural History of Cervical Human Papillomavirus Infections and Cervical Cancer. Gaps in Knowledge and Future Horizons.

Obstetrics and Gynecology Clinics of North America

Volumn 40, Issue 2, 2013, Pages 165-176

  Wheeler, Cosette Marie ^a,b  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Age specific HPV prevalence; Cervical intraepithelial neoplasia; Global cervical cancer burden; HPV genotypes; HPV immunity; HPV persistence; Human papillomavirus (HPV) infection; Human papillomavirus natural history

Indexed keywords

VIRUS DNA; VIRUS PROTEIN; WART VIRUS VACCINE;

CANCER GRADING; CANCER MORTALITY; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; COHORT ANALYSIS; DISEASE COURSE; GENOTYPE; HERPES SIMPLEX VIRUS 2; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; INCIDENCE; INFECTION RISK; KNOWLEDGE; LATENT VIRUS INFECTION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PARASITOSIS; PERSISTENT VIRUS INFECTION; PREDICTION; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REINFECTION; REVIEW; SECONDARY PREVENTION; SEROPREVALENCE; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS CELL INTERACTION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ADULT; AGE FACTORS; AGED; ANAL CANAL; ANIMALS; CERVICAL INTRAEPITHELIAL NEOPLASIA; DISEASE MODELS, ANIMAL; FEMALE; GENITAL DISEASES, FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MALE; MASS SCREENING; MICE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK FACTORS; SEXUAL BEHAVIOR; SEXUAL PARTNERS; SEXUALLY TRANSMITTED DISEASES, VIRAL; UTERINE CERVICAL DISEASES; UTERINE CERVICAL NEOPLASMS; VAGINA;

EID: 84878649931     PISSN: 08898545     EISSN: 15580474     Source Type: Journal    
DOI: 10.1016/j.ogc.2013.02.004     Document Type: Review

References (76)

1. Ebrahim S.H., McKenna M.T., Marks J.S. Sexual behaviour: related adverse health burden in the United States. Sex Transm Infect 2005, 81:38-40.
2. Burchell A., Richardson H., Mahmud S.M., et al. Modelling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montréal, Canada. Am J Epidemiol 2006, 163:534-543.
3. Barnabas R.V., Laukkanen P., Koskela P., et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006, 3:e138.
4. Hughes J.P., Garnett G.P., Koutsky L.A. The theoretical population level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2006, 13:631-639.
5. Veldhuijzen N.J., Snijders P.J., Reiss P., et al. Factors affecting transmission of mucosal human papillomavirus. Lancet Infect Dis 2010, 10:862-874.
6. Kines R.C., Thompson C.D., Lowy D.R., et al. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci U S A 2009, 106(48):20458-20463. 10.1073/pnas.0908502106.
7. Rodriguez A.C., Schiffman M., Herrero R., et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010, 102(5):315-324.
8. Winer R.L., Hughes J.P., Feng Q., et al. Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 2011, 20(4):699-707.
9. Molano M., Van den Brule A., Plummer M., et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003, 158:486-494.
10. Moscicki A.B., Schiffman M., Burchell A., et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012, 30(Suppl 5):F24-F33. 10.1016/j.vaccine.2012.05.089.
11. Moscicki A.B. Impact of HPV infection in adolescent populations. J Adolesc Health 2005, 37:S3-S9.
12. Ho G.Y., Burk R.D., Klein S., et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995, 87:1365-1371.
13. Rositch A.F., Koshiol J., Hudgens M.G., et al. Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer 2012, 10.1002/ijc.27828.
14. Muñoz N., Hernandez-Suarez G., Méndez F., Instituto Nacional de Cancerología HPV Study Group, et al. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br J Cancer 2009, 100(7):1184-1190. 10.1038/sj.bjc.6604972.
15. Koshiol J., Lindsay L., Pimenta J.M., et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008, 168(2):123-137. [review]. 10.1093/aje/kwn036.
16. Castle P.E., Rodriguez A.C., Burk R.D., et al. Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer. J Infect Dis 2011, 203(6):814-822.
17. Hariri S., Unger E.R., Sternberg M., et al. Prevalence of genital human papillomavirus among females in the United States, the national health and nutrition examination survey, 2003-2006. J Infect Dis 2011, 204:566-573.
18. Wheeler C.M., Hunt W.C., Cuzick J., et al. A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer 2013, 132(1):198-207. 10.1002/ijc.27608.
19. Franceschi S., Herrero R., Clifford G.M., et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006, 119:2677-2684.
20. Theiler R.N., Farr S.L., Karon J.M., et al. High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding. Obstet Gynecol 2010, 115(6):1150-1158. 10.1097/AOG.0b013e3181e00927.
21. Strickler H.D., Burk R.D., Fazzari M., et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005, 97(8):577-586.
22. Grulich A.E., van Leeuwen M.T., Falster M.O., et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370(9581):59-67. [review].
23. González P., Hildesheim A., Rodríguez A.C., et al. Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45 years. Cancer Epidemiol Biomarkers Prev 2010, 19(12):3044-3054. 10.1158/1055-9965.EPI-10-0645.
24. Gravitt P.E. The known unknowns of HPV natural history. J Clin Invest 2011, 121(12):4593-4599. [review]. 10.1172/JCI57149.
25. Zhang P., Nouri M., Brandsma J.L., et al. Induction of E6/E7 expression in cottontail rabbit papillomavirus latency following UV activation. Virology 1999, 263(2):388-394.
26. Maglennon G.A., McIntosh P., Doorbar J. Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology 2011, 414(2):153-163.
27. Insinga R.P., Perez G., Wheeler C.M., FUTURE I Investigators, et al. Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev 2010, 6:1585-1594. 10.1158/1055-9965.EPI-09-1235.
28. Trottier H., Ferreira S., Thomann P., et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res 2010, 70(21):8569-8577.
29. Rositch A.F., Burke A.E., Viscidi R.P., et al. Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Res 2012, 72(23):6183-6190. 10.1158/0008-5472.CAN-12-2635.
30. Gravitt P.E., Rositch A.F., Silver M.I., et al. A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States. J Infect Dis 2013, 207(2):272-280. 10.1093/infdis/jis660.
31. Winer R.L., Hughes J.P., Feng Q., et al. Prevalence and risk factors for oncogenic human papillomavirus infections in high-risk mid-adult women. Sex Transm Dis 2012, 39(11):848-856. 10.1097/OLQ.0b013e3182641f1c.
32. Preston C.M., Efstathiou S. Chapter 33. Molecular basis of HSV latency and reactivation. Human herpesviruses: biology, therapy, and immunoprophylaxis 2007, Cambridge University Press. A. Arvin, G. Campadelli-Fiume, E. Mocarski (Eds.).
33. Olsson S.E., Kjaer S., Sigurdsson K., et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009, 5:696-704.
34. Szarewski A., Poppe W.A., Skinner S.R., HPV PATRICIA Study Group, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 2012, 131(1):106-116. 10.1002/ijc.26362.
35. Apple R.J., Becker T.M., Wheeler C.M., et al. Comparison of human leukocyte antigen DR-DQ disease associations found with cervical dysplasia and invasive cervical carcinoma. J Natl Cancer Inst 1995, 87(6):427-436.
36. Wang S.S., Wheeler C.M., Hildesheim A., et al. Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. J Infect Dis 2001, 184(10):1310-1314.
37. Madeleine M.M., Johnson L.G., Smith A.G., et al. Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk. Cancer Res 2008, 68(9):3532-3539. 10.1158/0008-5472.CAN-07-6471.
38. Wang S.S., Hildesheim A., Gao X., et al. Comprehensive analysis of human leukocyte antigen class I alleles and cervical neoplasia in 3 epidemiologic studies. J Infect Dis 2002, 186(5):598-605.
39. Carter J.J., Koutsky L.A., Wipf G.C., et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996, 174:927-936.
40. Bernard H.U., Burk R.D., Chen Z., et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010, 401:70-79.
41. Schiffman M., Herrero R., Desalle R., et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005, 337:76-84.
42. Safaeian M., Porras C., Schiffman M., Costa Rican Vaccine Trial Group, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 2010, 102:1653-1662.
43. Viscidi R.P., Snyder B., Cu-Uvin S., et al. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev 2005, 14:283-288.
44. Smith B.C., McAndrew T., Chen Z., et al. The cervical microbiome over 7 years and a comparison of methodologies for its characterization. PLoS One 2012, 7(7):e40425. 10.1371/journal.pone.0040425.
45. Clarke M.A., Rodriguez A.C., Gage J.C., et al. A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection. BMC Infect Dis 2012, 12:33. 10.1186/1471-2334-12-33.
46. Castellsague X., Munoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003, 20-28.
47. Plummer M., Herrero R., Franceschi S., et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control 2003, 14:805-814.
48. Moreno V., Bosch F.X., Munoz N., et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002, 359:1085-1092.
49. Munoz N., Franceschi S., Bosetti C., et al. Role of parity and human papillomavirus in cervical cancer: The IARC multicentric case-control study. Lancet 2002, 359:1093-1101.
50. Serraino D., Carrieri P., Pradier C., et al. Risk of invasive cervical cancer among women with, or at risk for, HIV infection. Int J Cancer 1999, 82:334-337.
51. Frisch M., Biggar R.J., Goedert J.J. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000, 92:1500-1510.
52. Katki H.A., Kinney W.K., Fetterman B., et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011, 12(7):663-672. 10.1016/S1470-2045(11)70145-0.
53. Khan M.J., Castle P.E., Lorincz A.T., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005, 97:1072-1079.
54. Munoz N., Bosch F.X., de Sanjose S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
55. Saslow D., Solomon D., Lawson H.W., ACS-ASCCP-ASCP Cervical Cancer Guideline Committee, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012, 62(3):147-172. 10.3322/caac.21139.
56. Xi L.F., Koutsky L.A., Hildesheim A., et al. Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiol Biomarkers Prev 2007, 16(1):4-10.
57. Schiffman M., Rodriguez A.C., Chen Z., et al. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res 2010, 70(8):3159-3169. 10.1158/0008-5472.CAN-09-4179.
58. Tsoumpou I., Arbyn M., Kyrgiou M., et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009, 35(3):210-220. [review 50]. 10.1016/j.ctrv.2008.10.005.
59. Cuschieri K., Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2008, 17(10):2536-2545. [review]. 10.1158/1055-9965.EPI-08-0306.
60. Darragh T.M., Colgan T.J., Cox J.T., Members of LAST Project Work Groups, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 2012, 16(3):205-242. [review].
61. Waxman A.G., Chelmow D., Darragh T.M., et al. Revised terminology for cervical histopathology and its implications for management of high-grade squamous intraepithelial lesions of the cervix. Obstet Gynecol 2012, 120(6):1465-1471. 10.1097/AOG.0b013e31827001d5.
62. Martin C.M., O'Leary J.J. Histology of cervical intraepithelial neoplasia and the role of biomarkers. Best Pract Res Clin Obstet Gynaecol 2011, 25(5):605-615. [review]. 10.1016/j.bpobgyn.2011.04.005.
63. Wentzensen N., Sherman M.E., Schiffman M., et al. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol 2009, 112(2):293-299.
64. Wentzensen N., Sun C., Ghosh A., et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst 2012, 104(22):1738-1749. 10.1093/jnci/djs425.
65. Mirabello L., Schiffman M., Ghosh A., et al. Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. Int J Cancer 2013, 132(6):1412-1422. 10.1002/ijc.27750.
66. Lorincz A.T., Brentnall A.R., Vasiljević N., et al. HPV16 L1 and L2 DNA methylation predicts high grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology. Int J Cancer 2013, 10.1002/ijc.28050.
67. Schiffman M., Castle P.E., Jeronimo J., et al. Human papillomavirus and cervical cancer. Lancet 2007, 370(9590):890-907. [review].
68. Wright T.C., Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003, 348:489-490.
69. Wheeler C.M. Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer. Obstet Gynecol Clin North Am 2008, 35(4):519-536. [review], vii. 10.1016/j.ogc.2008.09.006.
70. Stoler M.H., Schiffman M., Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001, 285(11):1500-1505.
71. Castle P.E., Schiff man M., Wheeler C.M., et al. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009, 113:18-25.
72. Wright T.C., Massad L.S., Dunton C.J., 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis 2007, 11:223-239. [Erratum appears in J Low Genit Tract Dis 2008;12:63].
73. Gage J.C., Hanson V.W., Abbey K., ASCUS LSIL Triage Study (ALTS) Group, et al. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 2006, 108(2):264-272.
74. Stoler M.H., Vichnin M.D., Ferenczy A., FUTURE I, II and III Investigators, et al. The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials. Int J Cancer 2011, 128(6):1354-1362. 10.1002/ijc.25470.
75. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2011, 127:2893-2917.
76. de Sanjose S., Quint W.G., Alemany L., Retrospective International Survey and HPV Time Trends Study Group, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11(11):1048-1056. 10.1016/S1470-2045(10)70230-8.